Fortress Biotech Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FBIO Nasdaq 2836 http://www.fortressbiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fortress Biotech Inc

Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Mar 31st, 2023 12:00 pm
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights - Mar 31st, 2023 12:00 am
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights - Mar 30th, 2023 8:10 pm
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights - Mar 30th, 2023 8:01 pm
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights - Mar 29th, 2023 8:15 pm
Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights - Mar 29th, 2023 8:01 pm
Mustang Bio to Participate in Cantor’s The Future of Oncology Virtual Symposium - Mar 28th, 2023 12:30 pm
Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023 - Mar 22nd, 2023 1:00 pm
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial - Mar 16th, 2023 12:30 pm
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates - Mar 8th, 2023 9:01 pm
Journey Medical Corporation to Participate in the 35th Annual ROTH Conference - Mar 7th, 2023 1:30 pm
Fortress Biotech to Participate in Two March 2023 Investor Conferences - Mar 7th, 2023 1:00 pm
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy - Mar 2nd, 2023 1:00 pm
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma - Mar 2nd, 2023 12:00 pm
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Feb 21st, 2023 1:00 pm
The Executive Chairman of Fortress Biotech, Inc. (NASDAQ:FBIO), Lindsay Rosenwald, Just Bought 18% More Shares - Feb 19th, 2023 12:14 pm
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR - Feb 16th, 2023 1:30 pm
Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex - Feb 15th, 2023 1:30 pm
Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules - Feb 10th, 2023 5:50 pm
Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules - Feb 8th, 2023 1:00 pm